Lead party: OneBio Venture Studio (lead investor/buyer)
Coverage: Meridian Capital (investment and transaction tracker; data from Partner Researchers, editorially reviewed).
Target: LifeQ, Inc (private company) · Sector: Healthcare, Biotechnology · Countries of operation: South Africa
Transaction type: Investment · Asset class: Venture Capital · Strategy: Venture Equity · Instrument: Equity · Round: Series A · Deal amount: US$47m · Fund: 4Di Capital Fund II
Lead investor/buyer: OneBio Venture Studio · Investors/buyers: Invenfin Proprietary Limited, 4D Innovative Capital (Pty) Ltd, Allectus Capital, Mogul Capital, Tenhong Holdings, Analog Devices, Hannover Re, Convergence Partners Management (Pty) Ltd, Delos, Virgin Group, Lireas Holdings (Pty) Ltd., Allen & co, Acequia Capital, Rachel Diamond, Halls Investments, Bremer Investments, Errol Damelin, Dietco, OneBio Venture Studio, Stellar Capital Partners Limited, Nedbank Group Limited
Legal advisers: not identified in the source record.
Source: announced 26 May 2021. Original announcement: biospace.com.


